REGN vs UNH: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

REGN has stronger fundamentals based on our AI analysis.

REGN
REGENERON PHARMACEUTICALS, INC.
BUY
80%
Confidence
VS
UNH
UNITEDHEALTH GROUP INC
BUY
76%
Confidence

REGN vs UNH Fundamental Comparison

Metric REGN UNH
Revenue $14.3B $447.6B
Net Income $4.5B $12.1B
Net Margin 31.4% 2.7%
ROE 14.4% 12.0%
ROA 11.1% 3.9%
Current Ratio 4.13x 0.79x
Debt/Equity 0.06x 0.72x
EPS $41.48 $13.23

Green = Better metric | Red = Weaker metric

View Full REGN Analysis →
View Full UNH Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Strong Buy Undervalued Growth Dividend

You Might Also Compare

REGN vs AAPL UNH vs MSFT REGN vs GOOGL UNH vs AMZN

REGN vs UNH: Frequently Asked Questions

Is REGN or UNH a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), REGN has stronger fundamentals. REGN is rated BUY (80% confidence) while UNH is rated BUY (76% confidence). This is not investment advice.

How does REGN compare to UNH fundamentally?

REGENERON PHARMACEUTICALS, INC. has ROE of 14.4% vs UNITEDHEALTH GROUP INC's 12.0%. Net margins are 31.4% vs 2.7% respectively.

Which stock pays higher dividends, REGN or UNH?

REGN has a dividend yield of N/A or no dividend while UNH has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in REGN or UNH for long term?

For long-term investing, consider that REGN has BUY rating with 80% confidence, while UNH has BUY rating with 76% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about REGN vs UNH?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For REGN vs UNH, the AI consensus favors REGN based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.